For the astute biotechnology investor, Patrys offers a compelling opportunity. Our Deoxymab platform is a novel antibody exploiting synthetic lethality to fight cancer. So why is this unique? It targets cancer and is attracted to the DNA released from tumours; it has multiple modes of action to block several DDR systems; it has an excellent side-effect profile; and importantly, can cross the blood-brain barrier too.
Our shareholders are valued partners in our Company – explore our Investors Centre to learn more, subscribe to our email updates and we’ll keep you updated with our progress as we bring this exciting treatment to life.